A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light. For example, in 91 negative cancer trials presented at the American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) meetings, 29% of the presenters gave positive conclusions, typically focusing on positive subgroup data or some numerical advantage in the cohort receiving the drug.